2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Pathogenesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2411 Phase I study of prophylactic TCRαβ+ and CD19+ depleted donor lymphocyte infusion after allogeneic stem cell transplant in high-risk patients with hematologic malignancies

Hongtao Liu, MD,PhD, Kalyan Vg Nadiminti, MD2, Ross O Meyers, PhD3, Danielle F Atibalentja, MD,PhD4, Matthew James Brunner, MD5, Natalie S Callander, MD6, Michael Fallon, PharmD7, Zhubin Gahvari, MD8, Aric Hall, MD9, Vaishalee Kenkre, MD10, Ryan J. Mattison, MD11, Priyanka A. Pophali, MD12, Kieran Sahasrabudhe, MD13, Timothy Martin Schmidt, MD14, Jacques Galipeau, MD15
1 University of Wisconsin-Madison, Madison, Wisconsin, United States
2 University of Wisconsin-Madison, Madison, Wisconsin, United States
3 University of Wisconsin-Madison, Madison, Wisconsin, United States
4 University of Wisconsin-Madison, Madison, Wisconsin, United States
5 University of Wisconsin-Madison, Madison, Wisconsin, United States
6 University of Wisconsin-Madison, Madison, Wisconsin, United States
7 University of Wisconsin-Madison, Madison, Wisconsin, United States
8 University of Wisconsin-Madison, Madison, Wisconsin, United States
9 University of Wisconsin-Madison, Madison, Wisconsin, United States
10 University of Wisconsin-Madison, Madison, Wisconsin, United States
11 University of Wisconsin-Madison, Madison, Wisconsin, United States
12 University of Wisconsin-Madison, Madison, Wisconsin, United States
13 University of Wisconsin-Madison, Madison, Wisconsin, United States
14 University of Wisconsin-Madison, Madison, Wisconsin, United States
15 University of Wisconsin-Madison, Madison, Wisconsin, United States

Background:

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative therapy for patients with high-risk hematologic malignancies. However, disease relapses remain the leading cause of treatment failure. Donor lymphocyte infusion (DLI) is an established strategy to augment the graft-versus-leukemia (GVL) effect, but its broader application has been limited by the risk of graft-versus-host disease (GVHD) associated with unmodified DLI. Alpha-beta (αβ) T cells and CD19+ B-cells are major contributors to the development of GVHD. Meanwhile, post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis has become increasingly adopted. Although effective in reducing GVHD, PTCy not only depletes alloreactive T cells but also donor derived natural killer (NK) cells, NKT and γδ T cells, potentially increasing susceptibility to infections and disease relapse. Therefore, administration of DLI, enriched for mature donor NK, and γδ T cells while depleting GVHD-mediating αβ T cells and B cells (TCRαβ+/CD19+ depleted DLI), may enhance GVL activity, improve immune reconstitution, and reduce infectious complications without substantially increasing GVHD.

 

Study Design and Methods:  

This is the first prospective clinical trial evaluating prophylactic TCRαβ+/CD19+ depleted DLI following allo-SCT (ClinicalTrials.gov identifier: NCT07285668). This single-center, prospective phase I study is designed primarily to evaluate the safety of prophylactic TCRαβ+/CD19+ depleted DLI in patients undergoing allo-SCT for high-risk hematologic malignancies from related donors (matched/mismatched related donors or haploidentical donors). Secondary objectives include determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD), feasibility of product manufacturing, immune reconstitution, and preliminary efficacy outcomes including incidence of GVHD, disease relapses, progression-free survival, and overall survival. Results from this study will inform the design of a subsequent phase II efficacy trial.

Eligible patients are consented at the time of transplant consent. Stem cell donors undergo standard institutional evaluation and provide separate consent for collection of a donor lymphocyte product after stem cell donation. All transplant procedures, including conditioning regimens, PTCy-based GVHD prophylaxis, and post-transplant management, are performed according to institutional standards.

The investigational TCRαβ+/CD19+ depleted DLI is planned for administration at day 35 ± 7 after allo-SCT. Patients must meet predefined eligibility criteria before steady state donor lymphocyte apheresis is performed. The collected product is processed at the University of Wisconsin Program for Advanced Cell Therapy (PACT) GMP facility using the CliniMACS Prodigy® system (Miltenyi Biotec) under an FDA-approved Investigational Device Exemption (IDE). Three validation manufacturing runs using healthy donor products successfully achieved efficient depletion of TCRαβ+ T cells and CD19+ B cells. Following product release, the investigational product is administered intravenously within 24 hours of manufacturing completion.

Dose escalation is based on NK cell content, with planned dose levels of 1 × 106, 2 × 106, and 5 × 106 CD3−CD56+ cells/kg. A single steady-state donor apheresis is expected to provide sufficient NK cells to achieve all planned dose levels. Subjects who are temporarily ineligible for DLI administration may be reassessed and treated later if eligibility criteria are subsequently met.

A total of 28–38 patients will be enrolled, including 8–18 patients in a standard 3+3 dose-escalation phase followed by 20 patients in an expansion cohort treated at the MTD or MAD. Patients receiving TCRαβ+/CD19+ depleted DLI will be followed for relapse, survival, and safety for up to two years after allo-SCT or until study withdrawal or death.

The trial is currently ongoing. Manufacturing validation has been successfully completed, and the first patient has been enrolled and treated with investigational TCRαβ+/CD19+ depleted DLI without manufacturing issues.

Funding: Supported by Miltenyi Biotec

 

 

Hongtao Liu, MD,PhD: AbbiVie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)